Combination strategies have also been explored in PTCL, most notably the phase III ECHELON 2 trial, which compared BV in combination with the cytotoxic backbone of cyclophosphamide, doxorubicin, and prednisolone (BV-CHP) against the standard-of-care CHOP (cyclophosphamide, doxorubicine, vincristine, and prednisolone) in patients with newly diagnosed CD30-positive PTCL. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.